Emerald secures £1.5m pre-seed to build GP-led preventive care via unified records
This article covers Emerald, a healthtech startup that has raised £1.5m in a pre-seed funding round led by Boost Capital Partners and secured Care Quality Commission registration as it prepares UK expansion and the launch of proprietary coaching protocols in early 2026. The development aims to build a unified clinical record and GP-led preventive care pathway to support earlier, clinically regulated interventions for patients and scale preventive healthcare delivery across the UK.
Emerald, a healthtech startup, has raised £1.5m in a pre-seed funding round led by Boost Capital Partners to build a unified clinical record and GP-led preventive care pathway. The funding will support UK expansion and the launch of proprietary coaching protocols in early 2026, and comes as the company secures Care Quality Commission registration to operate as a regulated medical provider.
Why it matters
Preventive healthcare is often hampered by fragmented data spread across portals, wearables, PDFs and apps, which can delay intervention until conditions become serious. Emerald aims to bring those fragments together into a continuous health record paired with clinical oversight, a combination that could make earlier, actionable interventions more reliable and scalable.
CQC registration is a key practical milestone. It allows Emerald to move from interpreting data to delivering clinically regulated services such as diagnosis, prescribing and personalised care plans, changing its role from passive data platform to an active clinical provider.
Inside the product
Emerald aggregates health data and pairs each member with a dedicated GP who can review results, diagnose where appropriate, prescribe treatment and guide next steps. The company starts with a Baseline blood test that measures more than 115 biomarkers and is available at over 50 collection locations across the UK. Results are surfaced through an intuitive dashboard designed to help users track changes over time.
On the technology side Emerald operates a hybrid model: clinicians work alongside AI tools for monitoring and insight generation. The stated aim is to combine AI’s scalability with human oversight to reduce the risk of context-free or erroneous automated advice while increasing reach.
Who are the investors?
Emerald raised £1.5m in a pre-seed round led by Boost Capital Partners, with participation from investor Mark Fountain, VC firm Granatus Ventures and a group of angel investors. The company says the funds will accelerate its UK rollout and support the introduction of coaching protocols in early 2026, keeping development and clinical governance aligned with regulatory requirements.
In the announcement, Benjamin Torrero, Partner at Boost Capital Partners, said:
We believe that the next trillion dollar company will be one that gives people back control over their health. This can only be achieved with the right combination of an engaging product, a scientific approach and the capabilities to aggregate, gather, integrate and present health data in a comprehensive way for their users. In a world where people are increasingly concerned about prevention and public institutions are not ready to serve them, Emerald has built a rare combination of consumer-grade product velocity and deep clinical governance. They are building the operating system for longevity. They aren’t just riding the preventive health wave, they're positioned to lead it.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Alexander Badalyan, Co-founder & CEO at Emerald, said:
Right now, the trade-off is access versus quality. Unmoderated AI can scale access but can miss context, and when it’s wrong the cost can be high. Clinicians offer quality, but they can’t see everyone at once. We’re building the future where doctors, AI tools, and a unified data layer work together to reach more people with safer, higher-quality guidance.
In the announcement, Dr. Daniel McNally, Chief Medical Officer at Emerald, said:
With these regulatory approvals, we are moving beyond simple monitoring into active, early intervention. Emerald represents the transition from reactive medicine to a truly proactive clinical partner that lives with the patient providing the continuous, defensible data that modern healthcare demands.
The bigger picture
Emerald’s approach sits at the intersection of two trends: rising consumer interest in prevention and a push for regulated, clinically accountable digital health services. The hybrid GP-plus-AI model attempts to address a common criticism of healthtech products, which is scaling access without sacrificing clinical safety.
The raise also reflects continuing interest from UK healthtech investors in businesses that combine product design, data aggregation and regulatory compliance. As Emerald expands, its progress will be a useful indicator of whether clinically integrated preventive services can gain traction beyond early adopter markets and feed into wider NHS and private care pathways across the UK and Europe.
They've invested in Emerald
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK